Skip to main content
SpringerLink
Log in

Adjuvant Management of Advanced High-Risk Salivary Gland Malignancy

  • Chapter
  • First Online:
Difficult Decisions in Head and Neck Oncologic Surgery

Part of the book series: Difficult Decisions in Surgery: An Evidence-Based Approach ((DDSURGERY))

  • 609 Accesses

Abstract

Salivary gland malignancies (SGM) are a rare group of head and neck cancers. Surgical resection is the primary treatment modality but in patients with high risk features (close or positive margins, advanced T stage, high grade histology, nodal metastasis, bone invasion, perineural invasion, and extracapsular spread) there is debate on whether adjuvant radiation therapy (RT), systemic therapy or both might improve locoregional control and improve survival. We reviewed the literature surrounding the use of adjuvant therapy for the treatment of SGM with high risk features in patients who had already undergone surgical resection. Evidence based on retrospective series and database studies suggest that it is reasonable to offer adjuvant RT to these patients as it might improve locoregional control and offer possible survival benefit (quality of evidence: weak, strength of recommendation: weak). Regarding the use of adjuvant systemic therapy, evidence based on retrospective series and database studies suggest that it should not be offered to these patients as it has shown no benefit to locoregional control or survival (quality of evidence: weak, strength of recommendation: weak). Finally, we briefly discuss a clinical trial currently under way that should add to our understanding of the survival and toxicity outcomes of adding systemic therapy to radiation in this patient population.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 119.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Sunwoo J, Lewis J Jr, Tomeh C, McJunkin J. Malignant neoplasms of the salivary glands. In: Flint P, Haughey B, Lund V, Niparko J, Robbins T, Thomas R, Lesperance M, editors. Cummings otolaryngology. 6th ed. Canada: Elsevier Inc.; 2016. p. 1258–1280.e5. https://doi.org/10.1016/B978-1-4557-4696-5.00087-7.

    Chapter  Google Scholar 

  2. Barnes L, Eveson JW, Reichart P, Sidransky D. Pathology and genetics of head and neck tumours. In: WHO classification of tumours, vol. 9. France: IARC Publications; 2005. p. 163–75. https://doi.org/10.1016/j.urology.2004.09.048.

    Chapter  Google Scholar 

  3. Sung M-W, Kim KH, Kim J-W, et al. Clinicopathologic predictors and impact of distant metastasis from adenoid cystic carcinoma of the head and neck. Arch Otolaryngol Neck Surg. 2003;129(11):1193. https://doi.org/10.1001/archotol.129.11.1193.

    Article  Google Scholar 

  4. Seethala RR. An update on grading of salivary gland carcinomas. Head Neck Pathol. 2009;3(1):69–77. https://doi.org/10.1007/s12105-009-0102-9.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Terhaard CHJ, Lubsen H, Van der Tweel I, et al. Salivary gland carcinoma: independent prognostic factors for locoregional control, distant metastases, and overall survival: results of the Dutch head and neck oncology cooperative group. Head Neck. 2004;26(8):681–93. https://doi.org/10.1002/hed.10400.

    Article  PubMed  Google Scholar 

  6. Chen AM, Granchi PJ, Garcia J, Bucci MK, Fu KK, Eisele DW. Local-regional recurrence after surgery without postoperative irradiation for carcinomas of the major salivary glands: implications for adjuvant therapy. Int J Radiat Oncol Biol Phys. 2007;67(4):982–7. https://doi.org/10.1016/j.ijrobp.2006.10.043.

    Article  PubMed  Google Scholar 

  7. Terhaard CHJ, Lubsen H, Rasch CRN, et al. The role of radiotherapy in the treatment of malignant salivary gland tumors. Int J Radiat Oncol Biol Phys. 2005;61(1):103–11. https://doi.org/10.1016/j.ijrobp.2004.03.018.

    Article  PubMed  Google Scholar 

  8. Renehan AG, Gleave EN, Slevin NJ, McGurk M. Clinico-pathological and treatment-related factors influencing survival in parotid cancer. Br J Cancer. 1999;80(8):1296–300. https://doi.org/10.1038/sj.bjc.6690501.

    Article  CAS  PubMed  Google Scholar 

  9. Pohar S, Gay H, Rosenbaum P, et al. Malignant parotid tumors: presentation, clinical/pathologic prognostic factors, and treatment outcomes. Int J Radiat Oncol. 2005;61(1):112–8. https://doi.org/10.1016/j.ijrobp.2004.04.052.

    Article  Google Scholar 

  10. Bhattacharyya N, Fried MP. Determinants of survival in parotid gland carcinoma: a population-based study. Am J Otolaryngol. 2005;26(1):39–44. http://www.ncbi.nlm.nih.gov/pubmed/15635580. Accessed 15 June 2018.

    Article  PubMed  Google Scholar 

  11. Bakst RL, Su W, Ozbek U, et al. Adjuvant radiation for salivary gland malignancies is associated with improved survival: a National Cancer Database analysis. Adv Radiat Oncol. 2017;2(2):159–66. https://doi.org/10.1016/j.adro.2017.03.008.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Safdieh J, Givi B, Osborn V, Lederman A, Schwartz D, Schreiber D. Impact of adjuvant radiotherapy for malignant salivary gland Tumors. Otolaryngol Head Neck Surg. 2017;157(6):988–94. https://doi.org/10.1177/0194599817717661.

    Article  PubMed  Google Scholar 

  13. Cheraghlou S, Kuo P, Mehra S, et al. Adjuvant therapy in major salivary gland cancers: analysis of 8580 patients in the National Cancer Database. Head Neck. 2018;40(7):1343–55. https://doi.org/10.1002/hed.24984.

    Article  PubMed  Google Scholar 

  14. Mahmood U. Adjuvant radiation therapy for high-grade and/or locally advanced major salivary gland tumors. Arch Otolaryngol Neck Surg. 2011;137(10):1025. https://doi.org/10.1001/archoto.2011.158.

    Article  Google Scholar 

  15. Boffa DJ, Rosen JE, Mallin K, et al. Using the National Cancer Database for outcomes research. JAMA Oncol. 2017;3(12):1722. https://doi.org/10.1001/jamaoncol.2016.6905.

    Article  PubMed  Google Scholar 

  16. Al-Mamgani A, Van Rooij P, Verduijn GM, Meeuwis CA, Levendag PC. Long-term outcomes and quality of life of 186 patients with primary parotid carcinoma treated with surgery and radiotherapy at the Daniel den hoed cancer center. Int J Radiat Oncol Biol Phys. 2012;84(1):189–95. https://doi.org/10.1016/j.ijrobp.2011.11.045.

    Article  PubMed  Google Scholar 

  17. Cooper JS, Pajak TF, Forastiere AA, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med. 2004;350(19):1937–44. https://doi.org/10.1056/NEJMoa032646.

    Article  PubMed  Google Scholar 

  18. Bernier J, Domenge C, Ozsahin M, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med. 2004;350(19):1945–52. https://doi.org/10.1056/NEJMoa032641.

    Article  CAS  PubMed  Google Scholar 

  19. Fowler JF. Correction to Kasibhatla et al. How much radiation is the chemotherapy worth in advanced head and neck cancer? (Int J Radiat Oncol Biol Phys 2007;68:1491–1495). Int J Radiat Oncol. 2008;71(2):326–9. https://doi.org/10.1016/j.ijrobp.2008.01.052.

    Article  Google Scholar 

  20. Kasibhatla M, Kirkpatrick JP, Brizel DM. How much radiation is the chemotherapy worth in advanced head and neck cancer? Int J Radiat Oncol. 2007;68(5):1491–5. https://doi.org/10.1016/j.ijrobp.2007.03.025.

    Article  Google Scholar 

  21. Tanvetyanon T, Fisher K, Caudell J, Otto K, Padhya T, Trotti A. Adjuvant chemoradiotherapy versus with radiotherapy alone for locally advanced salivary gland carcinoma among older patients. Head Neck. 2016;38(6):863–70. https://doi.org/10.1002/hed.24172.

    Article  PubMed  Google Scholar 

  22. Amini A, Waxweiler TV, Brower JV, et al. Association of adjuvant chemoradiotherapy vs radiotherapy alone with survival in patients with resected major salivary gland carcinoma. JAMA Otolaryngol Neck Surg. 2016;142(11):1100. https://doi.org/10.1001/jamaoto.2016.2168.

    Article  Google Scholar 

  23. Mifsud MJ, Tanvetyanon T, Mccaffrey JC, et al. Adjuvant radiotherapy versus concurrent chemoradiotherapy for the management of high-risk salivary gland carcinomas. Head Neck. 2016;38(11):1628–33. https://doi.org/10.1002/hed.24484.

    Article  PubMed  Google Scholar 

  24. Gebhardt BJ, Ohr JP, Ferris RL, et al. Concurrent chemoradiotherapy in the adjuvant treatment of high-risk primary salivary gland malignancies. Am J Clin Oncol. 2018;41(9):888–93. https://doi.org/10.1097/COC.0000000000000386.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Tanvetyanon T, Qin D, Padhya T, et al. Outcomes of postoperative concurrent chemoradiotherapy for locally advanced major salivary gland carcinoma. Arch Otolaryngol Head Neck Surg. 2009;135(7):687–92. https://doi.org/10.1001/archoto.2009.70.

    Article  PubMed  Google Scholar 

  26. Hsieh C-E, Lin C-Y, Lee L-Y, et al. Adding concurrent chemotherapy to postoperative radiotherapy improves locoregional control but not overall survival in patients with salivary gland adenoid cystic carcinoma—a propensity score matched study. Radiat Oncol. 2016;11(1):47. https://doi.org/10.1186/s13014-016-0617-7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Radiation therapy with or without chemotherapy in treating patients with high-risk malignant salivary gland tumors that have been removed by surgery—full text view—ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01220583. Accessed 15 June 2018.

Download references

Author information

Authors and Affiliations

  1. Head and Neck Institute, Cleveland Clinic Foundation, Cleveland, OH, USA

    Chengetai Mahomva

  2. Section of Head and Neck Surgery and Oncology, Head and Neck Institute, Cleveland Clinic Foundation, Cleveland Clinic Lerner College of Medicine at Case Western Reserve University, Cleveland, OH, USA

    Jamie Ahn Ku

  3. Section of Facial Plastic and Reconstructive Surgery, Head and Neck Institute, Cleveland Clinic Foundation, Cleveland Clinic Lerner College of Medicine at Case Western Reserve University, Cleveland, OH, USA

    Jamie Ahn Ku

Authors
  1. Chengetai Mahomva
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jamie Ahn Ku
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jamie Ahn Ku .

Editor information

Editors and Affiliations

  1. Department of Surgery, Section of Otolaryngology-Head and Neck Surgery, University of Chicago, Chicago, IL, USA

    Zhen Gooi

  2. Department of Surgery, Section of Otolaryngology-Head and Neck Surgery, University of Chicago, Chicago, IL, USA

    Nishant Agrawal

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Mahomva, C., Ku, J.A. (2019). Adjuvant Management of Advanced High-Risk Salivary Gland Malignancy. In: Gooi, Z., Agrawal, N. (eds) Difficult Decisions in Head and Neck Oncologic Surgery. Difficult Decisions in Surgery: An Evidence-Based Approach. Springer, Cham. https://doi.org/10.1007/978-3-030-15123-2_19

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-15123-2_19

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-15122-5

  • Online ISBN: 978-3-030-15123-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation